IV Therapy, Peptides, GLP-1 Tirzepatide, Semaglutide, Retatrutide CME Certification for Nurses and Medical Directors

Fully Updated Monthly CME=Accredited Training

Beyond Injectables: Peptides, IV Therapy, and GLP-1 CME Certification Course

The first ACCME-, AMA-, and ANCC-accredited course covering the top 20 marketed peptides, elective IV therapy, GLP-1 weight loss (semaglutide, tirzepatide, retatrutide), compounding law, and medical director oversight in one curriculum. Updated monthly as the regulatory landscape changes. Credit valid September 1, 2026 through September 1, 2028. Order Today. Begin Learning Tonight. Print your Certificate when Finished.

11.5 Accredited CME Hours
11.5 AMA PRA Category 1 Credits and 11.5 ANCC contact hours including 6.5 pharmacotherapeutic hours. Self-paced, received the day of registration, 2-year access with free monthly updates to the Breaking News module.
6.5 Nursing Pharmacotherapeutic Hours Included. One of the only wellness-track CME courses that awards pharmacotherapeutic credit directly through ANCC. The majority of peptide and GLP-1 training programs route accreditation through intermediaries that cannot award pharmacology hours regardless of certificate wording.
ACCME Accredited AMA Category 1 ANCC CEU
Gregory P. Zengo, MD, FACOG

Gregory P. Zengo, MD, FACOG

Founder and Medical Director, PracticalCME. Board-certified physician and surgeon. 20 years of CME teaching. Author of the Beyond Injectables curriculum. Active medical director for multiple cash-pay wellness practices operating under current state scope and compounding law.

Updated October 30, 2026 HHS Peptide Enforcement Discretion Policy: On October 28, 2026, the HHS Secretary signed an interim enforcement discretion policy covering six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax, TB-500), published in the Federal Register on October 30, 2026 under docket HHS-OASH-2026-0496. The policy is route-specific, excludes IV administration for all six, does not cover blends or office stock, and does not bind state boards. Full analysis in Dr. Zengo's post: Update on the October 30 HHS Peptide Enforcement Discretion Policy: What It Means for Prescribers. The Breaking News module of this course was updated the same day.

Beyond Injectables is a 10-module, 11.5-hour accredited certification for registered nurses, nurse practitioners, physician assistants, physicians, and medical directors operating in cash-pay wellness practice. The curriculum covers the top 20 marketed peptides and their current regulatory status under the FDA 503A/503B compounding framework, elective IV therapy screening and administration (approximately 3.5 hours in Modules 7 and 8), GLP-1 weight loss protocols (semaglutide, tirzepatide, retatrutide) including dose titration and side effect management, the medical director role in supervising RN and NP injection and infusion practice, and state-specific scope-of-practice variance. The Breaking News module is updated monthly as HHS, FDA, and state boards act, with each regulatory development entering the curriculum within 24 to 48 hours. The course is taught by Gregory P. Zengo, MD, FACOG, a board-certified physician and surgeon with licensure in 8 states, 20 years of accredited CME authorship, and active medical director experience in multiple state scopes.

Why Clinicians Choose Beyond Injectables Over Non-Accredited Peptide Training

  • Direct ACCME, AMA, and ANCC Accreditation. Not routed through AAFP, state society, or specialty-board equivalence.
  • 6.5 Pharmacotherapeutic Hours. Direct ANCC pharmacotherapeutic credit for RNs and NPs.
  • Breaking News Module Updated Monthly. HHS, FDA, and state board actions within 24 to 48 hours of publication.
  • Full Regulatory Framework. FDA 503A/503B compounding law, state board positions, HHS enforcement discretion.
  • Medical Director Liability Covered. Supervising physician, nurse protocol, and delegation structures by state.
  • Current GLP-1 Protocols. Semaglutide, tirzepatide, and retatrutide including shortage delisting case law.
  • Top 20 Peptides, Not a Vendor Catalog. Evidence base and regulatory status for each, independent of any supplier.
  • Elective IV Therapy Done Right. ~3.5 hours covering screening, additives, administration, and documentation.
  • Downloadable Clinical Templates. Patient handouts for successful GLP-1 use customizable for your practice.
  • 2-Year Access With Free Updates. One tuition, continuous curriculum revision until September 1, 2028.
  • Named Faculty, Named Author. Dr. Zengo on the record, not an anonymous "board-certified physician."
  • Affirm Financing. 0% APR for 6 months available to those who qualify.
CME Credit: 11.5 AMA PRA Category 1 Credits (physicians and PAs via AAPA reciprocity), 11.5 ANCC contact hours including 6.5 pharmacotherapeutic hours (RNs and NPs), credit term September 1, 2026 through September 1, 2028. AANP credit pending. Jointly accredited by Amedco LLC and PracticalCME, LLC. Amedco LLC is accredited by the ACCME to provide continuing medical education for physicians.

0% Financing: Available at checkout through our partner Affirm. Terms subject to Affirm approval.
PracticalCME Beyond Injectables streaming course interface showing the module library, progress tracking, and current regulatory update module
The Learning Experience

A Modern Streaming Course for 2027

"Order today. Start learning tonight."

The Beyond Injectables course lives inside PracticalCME's own streaming learning platform, built the way clinicians actually consume CME in 2027. Works across phone, tablet, and desktop. The Breaking News module is separately updated so returning learners see every update the moment they log back in.

  • Access within a few hours of purchase, from any device.
  • Module progress saved automatically. Resume where you left off.
  • Desktop responsive or mobile device app. Same interface, same progress, every screen. Even watch offline.
  • Downloadable certificate issued the moment you complete the final module quiz.
  • 2 years of access with free monthly updates

No training course alters the legal scope of practice as defined by the medical/nursing boards in your home state/country. Please review all state/country requirements for supervision for these procedures prior to adding them to your practice.

🛒REGISTER NOW: Peptides, IVs, GLP-1s, and the Wellness Frontier

Peptides, IV Hydration, GLP-1s and the Wellness Frontier

The Beyond Injectables Series · Detailed Course Outline

Accreditation: This activity has applied for 11.5 hours ACCME / AMA PRA Category 1 Credit™, with AAPA reciprocity for physician assistants and 11.5 ANCC contact hours (including 6.5 pharmacology hours) for nurses and nurse practitioners. Credit term September 1, 2026 through September 1, 2028

Format & depth: Online enduring material · approximately 11.5 hours of instruction across ten modules, spanning peptides, medically supervised GLP-1 weight loss, and elective IV therapy.

1. Stress, Nutrition, and the Unforced Errors Behind Common Symptoms ~50 min

  • How everyday modifiable inputs drive fatigue, weight gain, poor sleep, and low libido
  • The HPA axis and chronic stress: the cortisol rhythm, sleep, dehydration, alcohol, stimulants, and processed food
  • Ultra-processed food, gluten, and dairy: the gut microbiome, inflammation, and the blood-sugar response
  • Dietary supplements and caffeine in the wellness work-up
  • Behavior-change counseling as billable clinical value

2. Scope, Venue, and the Legal Framework for Nurses, NPs, PAs, and Medical Directors ~55 min

  • RN, NP, and PA scope of practice for IV therapy, peptides, and GLP-1 prescribing
  • Full practice authority, supervision models, and the good-faith examination (synchronous and asynchronous telehealth)
  • Standing orders and protocols as the mechanism for RN delivery
  • 503A and 503B compounding and legal product sourcing
  • HIPAA in cash-pay practice, documentation, and charting standards
  • Venue options: clinical office, salon suite, shared medical office, and mobile or in-home

3. Peptides: History and the Compounding Pharmacy Channel ~25 min

  • How compounding became a sales channel, from the craft-pharmacy baseline through the telehealth era
  • The GLP-1 shortage era, the expansion of compounding, and its conclusion
  • The four categories: FDA-approved drug, compounded preparation, research chemical, and dietary supplement
  • Decoding supplier marketing: cGMP, purity, and endotoxin claims
  • Supplier due diligence and the questions every purchaser should ask

4. The Top 20 Peptides: Evidence, Eligibility, and Regulatory Status ~1.5 hrs

  • An evidence review of the twenty most-marketed peptides: human trials versus animal and anecdotal data
  • Compound-by-compound coverage of BPC-157, TB-500, Sermorelin, CJC-1295, Ipamorelin, Tesamorelin, AOD-9604, GHK-Cu, Thymosin alpha-1, MOTS-c, Epitalon, KPV, Semax, Selank, DiHexa, PT-141 (Bremelanotide), Melanotan-II, methylene blue, NAD+, NR, NMN, TUDCA, and collagen peptides
  • Growth hormone secretagogues, tissue-repair peptides, and cosmetic and sexual-health agents
  • The FDA Bulks List, Categories 1 and 2, and the 2026 advisory-committee updates
  • A decision framework you can apply to any new compound

5. GLP-1 Weight Loss in Clinical Practice: Semaglutide, Tirzepatide, and the Full Protocol ~2 hrs

  • Semaglutide versus tirzepatide: Wegovy, Zepbound, Ozempic, and Mounjaro, mechanisms, dosing, and pivotal trial data
  • Candidate selection, contraindications (medullary thyroid carcinoma, MEN2), baseline labs, and pregnancy screening
  • Titration, dose holds, side-effect management, and long-term maintenance
  • Visit-by-visit counseling: the menu, muscle preservation, and the slow responder
  • Cash-pay design, self-pay pharmacies, and prior authorization

6. Emerging Weight-Loss Agents, Including Retatrutide and Oral GLP-1s ~50 min

  • Retatrutide: the triple-agonist mechanism and the TRIUMPH program
  • Oral GLP-1s: oral semaglutide (Rybelsus, oral Wegovy) and orforglipron (Foundayo)
  • Cagrilintide, CagriSema, survodutide, amylin analogs, and combination therapy, plus Lorcaserin, Tesofensine, SLU-PP-332, BAM-15, and 5-Amino-1MQ
  • Reading pipeline data: pivotal readouts, effect size, and safety signals
  • Participating in clinical trials individually or as a clinic

7. Elective IV Therapy: History, Legal Framework, and Patient Screening ~35 min

  • Intravenous therapy and its role in wellness practice, from the Myers cocktail forward
  • The evidence base for vitamin drips, hangover IVs, and NAD+ infusions
  • The legal and regulatory framework, including Jenifer’s Law (Texas HB 3749) and national trends
  • Patient screening, informed consent, and marketing guidelines

8. Elective IV Therapy Done Right: Additives, Compounding, and Administration ~3 hrs

  • Patient screening, pre-screening to prevent complications, and what labs can and cannot tell you
  • The complete additive menu, reviewed for dosing, evidence, and safety: B-complex, B12, vitamin C, magnesium, calcium, glutathione, NAD+, and more
  • Base fluids, IV technique, monitoring, and patient positioning
  • Compounding standards, including USP guidance, and bag preparation
  • Menu formulations and the elements of a properly documented IV order

9. The Medical Director Role, Oversight, and Practice Ownership ~35 min

  • What the supervising physician signs: delegated authority and the oversight chain
  • Medical director qualifications, licensure, and supervision models
  • Documentation that demonstrates genuine oversight
  • Ownership, the corporate practice of medicine (CPOM), and the management services organization (MSO) structure
  • Employment versus ownership considerations

10. Synthesizing the Services into an Integrated Wellness Practice ~15 min

  • Integrating all three service lines into one coherent practice model
  • A decision framework for every service you offer
  • The compliant business model, subscription, and membership design
  • The provider-patient partnership and trust as a retention strategy
  • The bridge to companion training in aesthetics, hormone therapy (BHRT), and weight loss

11. Breaking News ~variable

  • The latest news on Peptides, IV Hydration, and GLP-1
  • New approvals and warnings
  • ⭐Updated MONTHLY⭐

Beyond Injectables™ is PracticalCME’s suite of fully accredited online CME training courses designed for busy nurses, nurse practitioners, and physician assistants who want to enter the most in-demand wellness and aesthetic services, and who demand the most rigorous, evidence-based, MD-taught training before doing so. For over 18 years, PracticalCME has been a leader in small-group, physician-led training in injectable procedures like Botulinum Toxin, Dermal Fillers, PRP, and Microneedling. As our students have gone on to successful careers, many want the same level of training for non-aesthetic and non-injectable services so they can better treat patients inside and out. Every course is vendor-neutral, evidence-based, and accredited for ACCME / AMA PRA Category 1 Credit™ with AAPA reciprocity and ANCC contact hours, including pharmacology hours. The series includes:

  1. Peptides, IVs, GLP-1s and the Wellness Frontier — comprehensive training in GLP-1 weight loss (semaglutide, tirzepatide), peptide therapy, IV wellness practice, and compounding law.  AVAILABLE NOW
  2. Saliva Testing and Bio-Identical Hormone Therapy (BHRT) — hormone optimization, saliva testing, and treatment of fatigue, low libido, and menopause symptoms (AVAILABLE NOW)
  3. Evidence-Based Weight Loss and GLP-1 Master Course — the complete deep-dive into medical weight loss, GLP-1 prescribing, and long-term patient management (available now, revision planned Q1 2027)
  4. Neurotransmitter and GI Testing and Treatment — the gut-brain axis, neurotransmitter testing, stress, and GI health protocols (available now, revision planned Q2 2027)
  5. Non-Injectable Aesthetics for Nurses — evidence-based aesthetic services including chemical peels, microdermabrasion, and dermaplaning (new course planned for Q4 2026)

Every Beyond Injectables™ course is taught by a board-certified physician and built on the same principle: clinical judgment first, sound business practice second, and no vendor hype. Whether you are an RN, NP, or PA launching a cash-pay wellness clinic or a medical director evaluating what your practice should safely offer, this series delivers the accredited, up-to-date training you need to practice confidently and defensibly in 2026 and beyond.

Peptides, IVs, GLP-1s and The Wellness Frontier

This course is approved for 11.5 ACCME, AMA Category 1, and ANCC credits with 6.5 pharmacotherapeutic hours for Nurses and Nurse Practitioners.

Accreditation dates:  September 1, 2026 through September 1, 2028

Joint Accreditation Statement

In support of improving patient care, this Jointly accredited CME approval logo activity has been planned and implemented by and Practical CME. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare
team.
Amedco Joint Accreditation Provider Number: 4008163
Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this material for a maximum of 11.5 AMA PRA Category 1 Credits for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of 11.5 ANCC contact hours including 6.5 pharmacotherapeutic hours.

First, Reserve your Online Training Seat in any Beyond Injectables Aesthetic or Wellness Training Course.

You will have 2 Years of Unlimited Online Access wtih Free Updates pushed to your account periodically as needed and new drugs are approved.

online-video-cme-courses

Then Watch the Online training at your own pace.  Follow clickable links and interact with our faculty for any questions you have.  When finished, complete the online post-test.

DOWNLOAD/PRINT CME CERTIFICATE

Frequently Asked Questions

What does this GLP-1 and peptide CME course cover?

The course covers medical weight loss with GLP-1 medications including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), the top 20 marketed peptides, IV wellness therapy, and emerging agents such as retatrutide, oral semaglutide, and orforglipron. It teaches candidate selection, contraindication screening, prescribing and titration, patient counseling, compounding law (503A and 503B), scope of practice, and medical director liability.

Is this the best IV therapy certification course for nurses and NPs?

For nurses and nurse practitioners specifically looking for an accredited IV therapy certification course, this is currently the only ACCME/AMA and ANCC-accredited program combining IV wellness therapy, GLP-1 weight loss, and peptide therapy in one course. Rather than a standalone IV therapy certification course focused only on additive selection, this program teaches IV therapy within its full clinical and legal context: scope of practice, patient screening, G6PD safety, compounding law, and defensible practice design. Modules 7 and 8 deliver dedicated IV therapy training; the surrounding modules provide the wellness practice framework that makes IV therapy sustainable and safe.

Is this course accredited for CME and CE credit?

Yes. The activity is jointly accredited by Amedco LLC and PracticalCME, LLC, and is now active for full CME and CE credit through September 1, 2028. Physicians earn 11.5 AMA PRA Category 1 Credits™ (with AAPA reciprocity for physician assistants), and nurses and nurse practitioners earn 11.5 ANCC contact hours including 6.5 pharmacotherapeutic contact hours. This is genuine accreditation in a field that too often runs on vendor marketing, rumor, and hearsay.

Who should take this course?

Registered nurses, nurse practitioners, physician assistants, and physicians serving as medical directors of wellness, weight loss, aesthetic, or IV therapy clinics. It is built for clinicians who want evidence-based, vendor-neutral training before offering GLP-1 weight loss, peptide therapy, or IV services.

Does the course teach how to prescribe and dose GLP-1 medications?

Yes. It walks through the full clinical workup, baseline labs, contraindication screening, starting doses, the escalation schedule, dose holds, maintenance dosing, side-effect management, and visit-by-visit patient counseling for semaglutide and tirzepatide, plus the oral GLP-1 options.

Does it cover retatrutide and other emerging weight-loss agents?

Yes. Because CME is education, the course covers retatrutide, oral semaglutide, and orforglipron so clinicians understand every therapy patients ask about and are prepared as these agents reach the market. It also teaches how to respond to patients requesting agents that are not yet FDA-approved.

Does the course explain peptide compounding law and the top marketed peptides?

Yes. It reviews the 20 most-marketed peptides with their real human evidence, the 503A Bulks List status, and WADA considerations, and it explains the difference between an FDA-approved drug, a compounded preparation, a research chemical, and a supplement, including how to decode supplier marketing.

Does it cover IV therapy and vitamin drips?

Yes. The course covers what IV hydration and vitamin infusions do and do not do, legitimate medical indications, patient screening, G6PD safety before high-dose vitamin C, defensible additives, and the legal and marketing framework for an IV wellness practice.

Is the course online and self-paced?

Yes. It is a fully online, self-paced video training course from PracticalCME, taught by a board-certified physician, and accessible on demand from any device.

Does it address scope of practice and medical director liability?

Yes. It covers RN, NP, and PA scope for these services, standing orders, the good-faith exam and telehealth rules, documentation that protects the practice, and what a supervising physician is exposed to when signing on as medical director.
  • Training Course Options

  • Customer Support